You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 293 No. 9, March 2, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Lipids and Lipid Disorders
 •Otolaryngology/ Head & Neck Surgery
 •Endocrine Disease of Head & Neck
 •Endocrine Diseases
 •Thyroid/ Parathyroid Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Subclinical Thyroid Disease and Cardiovascular Disease

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their Scientific Review and Clinical Applications article on subclinical thyroid disease,1 Dr Surks and colleagues stated that although several studies suggested that levothyroxine therapy will reduce total and low-density lipoprotein (LDL) cholesterol levels in patients with subclinical hypothyroidism,2 this finding had not been confirmed in randomized placebo-controlled trials, including a study for which 2 of us were authors.3 This is not accurate. In our study, patients with subclinical hypothyroidism had total and LDL cholesterol levels significantly higher than controls, which correlated with baseline serum thyrotropin (TSH) levels. Six months of levothyroxine therapy resulted in a significant decrease of both total and LDL cholesterol concentrations proportional to the baseline levels (–8.0% and –10.2%, respectively). Although greater improvement in total and LDL cholesterol levels was detected in patients with TSH levels of more than 6.0 mIU/L (–11.3% and –15.6%, respectively), reduction in both total and LDL cholesterol . . . [Full Text of this Article]

Nadia Caraccio, MD; Angela Dardano, MD; Fabio Monzani, MD
fmonzani@med.unipi.it
Department of Internal Medicine
University of Pisa School of Medicine
Pisa, Italy



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Subclinical Thyroid Disease and Cardiovascular Disease—Reply
Martin I. Surks
JAMA. 2005;293(9):1060.
EXTRACT | FULL TEXT  

Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management
Martin I. Surks, Eduardo Ortiz, Gilbert H. Daniels, Clark T. Sawin, Nananda F. Col, Rhoda H. Cobin, Jayne A. Franklyn, Jerome M. Hershman, Kenneth D. Burman, Margo A. Denke, Colum Gorman, Richard S. Cooper, and Neil J. Weissman
JAMA. 2004;291(2):228-238.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.